Samalizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD200 |
Clinical data | |
ATC code | none |
Identifiers | |
CAS Number | 1073059-33-2 |
ChemSpider | none |
UNII | 64EUX713G6 |
Chemical and physical data | |
Formula | C6542H10086N1702O2102S46 |
Molar mass | 147.7 kg/mol |
(what is this?) (verify) |
Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1]
Samalizumab was developed by Alexion Pharmaceuticals.
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.
This article is issued from Wikipedia - version of the 9/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.